Scarica l'app Stockscreener
4.13
5.92%
-0.26
Pre-mercato:
4.20
0.07
+1.69%
Precedente Chiudi:
$4.39
Aprire:
$4.5
Volume 24 ore:
1.10M
Relative Volume:
1.20
Capitalizzazione di mercato:
$132.97M
Reddito:
-
Utile/perdita netta:
$-29.25M
Rapporto P/E:
-3.4823
EPS:
-1.186
Flusso di cassa netto:
$-22.80M
1 W Prestazione:
-0.60%
1M Prestazione:
-16.57%
6M Prestazione:
+33.66%
1 anno Prestazione:
-39.44%
Intervallo 1D:
$4.07
$4.55
Intervallo di 1 settimana:
$4.07
$4.55
Portata 52W:
$2.39
$20.71
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Nome
Sagimet Biosciences Inc
Settore
Industria
Telefono
(650) 561-8600
Indirizzo
155 BOVET RD., SUITE 303, SAN MATEO
Confronta SGMT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
4.13 | 132.97M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-06 | Iniziato | Oppenheimer | Outperform |
| 2024-11-12 | Iniziato | UBS | Buy |
| 2024-06-28 | Downgrade | Goldman | Buy → Neutral |
| 2024-05-02 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-25 | Iniziato | Leerink Partners | Outperform |
| 2023-08-08 | Iniziato | Goldman | Buy |
| 2023-08-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-08-08 | Iniziato | Piper Sandler | Overweight |
| 2023-08-08 | Iniziato | TD Cowen | Outperform |
Mostra tutto
Sagimet Biosciences Inc Borsa (SGMT) Ultime notizie
With 43% stake, Sagimet Biosciences Inc. (NASDAQ:SGMT) seems to have captured institutional investors' interest - Simply Wall St
Sagimet Biosciences' SWOT analysis: promising NASH drug faces funding hurdles - Investing.com
Geode Capital Management LLC Acquires 91,246 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
When (SGMT) Moves Investors should Listen - Stock Traders Daily
Gaining Ground: Sagimet Biosciences Inc (SGMT) Closes Lower at 5.37, Down -3.59 - The Dwinnex
Barclays PLC Boosts Stock Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Stock Soars To 10-Month High, Retail’s Fired Up Over Presentation On Lead MASH Drug Candidate - MSN
Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference - The Manila Times
Sagimet to Present Breakthrough MASH Treatment Data at MASH-TAG Conference 2025 - StockTitan
Sagimet Biosciences Updates Investor Presentation in Recent 8-K Filing - Defense World
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $23.00 Average PT from Analysts - Defense World
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
(SGMT) Trading Advice - Stock Traders Daily
Sagimet Biosciences: A Rising Star in the Fight Against NASH with Promising Clinical Data for Denifanstat - mediahousepress
Sagimet Biosciences up 30% on strong clinical stage data - Mugglehead
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket - Benzinga
(SGMT) On The My Stocks Page - Stock Traders Daily
Sagimet Biosciences (NASDAQ:SGMT) Research Coverage Started at Oppenheimer - Defense World
Sagimet Biosciences (NASDAQ:SGMT) Now Covered by Analysts at Oppenheimer - MarketBeat
Oppenheimer Initiates Coverage of Sagimet Biosciences (SGMT) with Outperform Recommendation - MSN
Sagimet started at outperform by Oppenheimer, MASH drug cited - MSN
Sagimet started at outperform by Oppenheimer, MASH drug cited (NASDAQ:SGMT) - Seeking Alpha
Oppenheimer sets $30 target on Sagimet Biosciences shares - Investing.com
How To Trade (SGMT) - Stock Traders Daily
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Sagimet Biosciences to Present at Piper Sandler Healthcare Conference | SGMT Stock News - StockTitan
Sagimet Biosciences participates ik,on No - TipRanks
Sagimet Biosciences Inc. Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLDthe Liver Meeting 2024 - Marketscreener.com
HC Wainwright Reaffirms “Buy” Rating for Sagimet Biosciences (NASDAQ:SGMT) - Defense World
Sagimet Biosciences keeps stock target with Buy rating on phase 3 program - Investing.com
Sagimet Biosciences presents clinical denifanstat, preclinical FASN inhibitor da - TipRanks
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLDThe Liver Meeting® 2024 - The Manila Times
Sagimet Biosciences Presents Clinical Denifanstat and - GlobeNewswire
Sagimet's Denifanstat Shows 49% Fibrosis Improvement in Phase 2b MASH Trial | SGMT Stock News - StockTitan
Institutional investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) see US$36m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
Sagimet Biosciences' (SGMT) Buy Rating Reiterated at HC Wainwright - MarketBeat
Steven Cohen's Strategic Acquisition in Sagimet Biosciences Inc - GuruFocus.com
Hillhouse Capital Management's Strategic Reduction in Sagimet Bi - GuruFocus.com
Baker Bros. Advisors LP Increases Stake in Sagimet Biosciences I - GuruFocus.com
Sagimet Biosciences Inc Azioni (SGMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Sagimet Biosciences Inc Azioni (SGMT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Martins Eduardo Bruno | Chief Medical Officer |
Jul 19 '24 |
Sale |
3.10 |
8,357 |
25,910 |
81,213 |
| Rozek Elizabeth | General Counsel and CCO |
Jul 19 '24 |
Sale |
3.10 |
10,914 |
33,830 |
160,506 |
| Kemble George | Executive Chairman |
Jul 19 '24 |
Sale |
3.10 |
14,062 |
43,605 |
142,318 |
| Happel David | President & CEO |
Mar 26 '24 |
Buy |
5.27 |
12,100 |
63,731 |
639,200 |
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):